AxoGen, Inc. (AXGN)
Largest Insider Buys in Sector
AXGN Stock Price History Chart
AXGN Stock Performance
About AxoGen, Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM …
Insider Activity of AxoGen, Inc.
Over the last 12 months, insiders at AxoGen, Inc. have bought $0 and sold $1.07M worth of AxoGen, Inc. stock.
On average, over the past 5 years, insiders at AxoGen, Inc. have bought $188,940 and sold $2.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $62,240 was made by Wendell Amy McBride (director) on 2023‑09‑06.
List of Insider Buy and Sell Transactions, AxoGen, Inc.
| 2024-03-21 | Sale | CEO | 39,280 0.091% | $7.68 | $301,670 | +3.46% | ||
| 2024-03-21 | Sale | Chief Innovation Officer | 4,578 0.0106% | $7.68 | $35,159 | +3.46% | ||
| 2024-03-21 | Sale | Chief R&D Officer | 6,881 0.0159% | $7.68 | $52,846 | +3.46% | ||
| 2024-03-21 | Sale | VP Operations | 6,033 0.014% | $7.68 | $46,333 | +3.46% | ||
| 2024-03-07 | Sale | director | 25,000 0.0581% | $9.00 | $225,000 | -12.20% | ||
| 2024-03-07 | Sale | VP Operations | 36,310 0.0826% | $8.81 | $319,891 | -12.20% | ||
| 2023-12-11 | Sale | EVP & Chief Financial Officer | 12,500 0.0291% | $7.50 | $93,809 | +8.22% | ||
| 2023-09-06 | director | 10,000 0.0235% | $6.22 | $62,240 | +16.26% | |||
| 2023-08-23 | director | 10,000 0.0234% | $6.56 | $65,600 | +7.44% | |||
| 2023-08-16 | director | 10,000 0.0252% | $6.11 | $61,100 | +23.36% | |||
| 2023-06-01 | Sale | director | 41,980 0.0994% | $8.71 | $365,780 | -18.63% | ||
| 2023-05-23 | Sale | director | 7,468 0.0176% | $9.23 | $68,899 | -21.55% | ||
| 2023-02-01 | Sale | EVP & Chief Financial Officer | 14,550 0.0348% | $9.36 | $136,188 | -11.25% | ||
| 2023-01-31 | Sale | EVP & Chief Financial Officer | 14,320 0.0343% | $9.55 | $136,756 | -12.94% | ||
| 2023-01-30 | Sale | EVP & Chief Financial Officer | 14,111 0.0334% | $9.69 | $136,736 | -15.26% | ||
| 2023-01-27 | Sale | EVP & Chief Financial Officer | 20,940 0.0495% | $10.16 | $212,750 | -19.29% | ||
| 2022-11-16 | Sale | EVP & Chief Financial Officer | 10,649 0.027% | $11.88 | $126,510 | -24.25% | ||
| 2022-11-14 | Sale | director | 13,000 0.0339% | $12.74 | $165,620 | -27.03% | ||
| 2022-11-08 | Sale | director | 13,000 0.0337% | $12.50 | $162,500 | -25.66% | ||
| 2022-08-10 | Sale | 8,886 0.0204% | $9.70 | $86,159 | -4.15% |
Insider Historical Profitability
| Zaderej Karen L. | CEO | 1124565 2.5658% | $15.19 | 9 | 8 | +15.63% |
| Freitag Gregory Gene | director | 271594 0.6197% | $15.19 | 6 | 12 | +24.07% |
| MARIANI PETER J | EVP & Chief Financial Officer | 63603 0.1451% | $15.19 | 1 | 9 | +19.13% |
| Mandato Joseph M | director | 1226773 2.7989% | $15.19 | 1 | 4 | +61.29% |
| Hopfenspirger Larry | 10 percent owner | 426066 0.9721% | $15.19 | 1 | 0 |
Institutional Investor Ownership
| Arrowmark Colorado Holdings Llc | $38.14M | 10.82 | 4.73M | -8.26% | -$3.43M | 0.1 | |
| BlackRock | $26.08M | 7.4 | 3.23M | -3.31% | -$892,267.67 | <0.01 | |
| Morgan Stanley | $25.67M | 7.28 | 3.18M | +3.18% | +$791,997.89 | <0.01 | |
| Soleus Capital Management, L.P. | $25.06M | 7.11 | 3.11M | +19.65% | +$4.12M | 0.1 | |
| The Vanguard Group | $19.46M | 5.52 | 2.41M | -2.19% | -$436,530.51 | <0.0001 |